文章摘要
许晓松.荷瘤乳腺癌女性外周血髓样来源抑制性细胞表达浓度及意义分析[J].中国医药导刊,2017,19(10):993-996.
荷瘤乳腺癌女性外周血髓样来源抑制性细胞表达浓度及意义分析
Expression Concentration of Myeloid-derived Suppressor Cells in Peripheral Blood of Tumor-bearing Females With Breast Cancer and the Significance Analysis
投稿时间:2017-06-27  修订日期:2017-08-29
DOI:
中文关键词: 乳腺癌/荷瘤  髓样来源的抑制性细胞/外周血  临床分期  病理特征
英文关键词: Breast cancer/tumor-bearing  Myeloid-derived suppressor cells (MDSCs)/peripheral blood  Clinical stages  Pathological characteristics
基金项目:辽宁省2011年科学技术计划资助项目(项目编号:2011225019;项目名称:高发恶性肿瘤防治技术研究与临床评价)
作者单位E-mail
许晓松 阜新矿业集团(矿务局)总医院肿瘤外科 13841832942@126.com 
摘要点击次数: 509
全文下载次数: 200
中文摘要:
      目的: 分析荷瘤乳腺癌女性外周血髓样来源抑制性细胞(MDSC)表达浓度及意义。方法:连续选取2015年1月至2016年12月经我院肿瘤外科初次确诊的女性乳腺癌患者41例,入选对象均未接受过各种治疗。对照组选择同期参加我院医院体检结论健康志愿者26例。乳腺癌组在开始治疗前接受了外周血MDSC(CD11b+、CD33+、CD14-)表达浓度检测,对照组在体检期间接受了相同检查。结果:荷瘤乳腺癌女性患者外周血MDSC表达浓度明显高于对照组,不同年龄荷瘤乳腺癌女性外周血MDSC表达浓度均明显高于相同年龄对照组(P均<0.001)。不同临床表现荷瘤乳腺癌女性外周血MDSC表达浓度比较中, 肿瘤淋巴结转移(TNM)Ⅲ期组外周血MDSC表达浓度明显高于TNM Ⅰ期和Ⅱ期组(P<0.01),而年龄小组与年龄大组外周血MDSC表达浓度分布无明显区别(P>0.05)。不同病理情况荷瘤乳腺癌女性外周血MDSC表达浓度比较中,淋巴结转移组外周血MDSC表达浓度明显高于无淋巴结转移组(P<0.01),而肿瘤体积小组与肿瘤体积大组、组织学Ⅰ级和Ⅱ级组与组织学Ⅲ级组外周血MDSC表达浓度分布均无明显区别(P均>0.05)。不同分子学分型荷瘤乳腺癌女性外周血MDSC表达浓度比较中, Luminal A、Luminal B、HER-2过表达型和三阴乳腺癌等分子学分型荷瘤乳腺癌女性外周血MDSC表达浓度分布均无明显区别(P均>0.05)。结论:外周血MDSC可作为乳腺癌生物学辅助诊断特异性标识,且与乳腺癌临床TNM分期以及有无淋巴结转移关系密切。
英文摘要:
      Objective:To analyze the expression and significance of myeloid-derived suppressor cells (MDSCs) in the peripheral blood of tumor-bearing females with breast cancer.Methods:41 female patients who were firstly diagnosed as breast cancer by the department of tumor surgery in our hospital were successively selected from January 2015 to December 2016, and all the enrolled subjects did not accept any treatments.26 volunteers were selected as the control group from the physical examinees who were concluded as healthy during the same period. The patients in the breast cancer group accepted the detection of the expression concentrations of MDSCs (CD11b+, CD33+ and CD14-) in the peripheral blood before treatment,and the subjects in the control group accepted the same detection during the physical examination.Results:The expression concentrations of MDSCs in the peripheral blood of tumor-bearing female patients with breast cancer were obviously higher than those in the control group,and the the expression concentrations of MDSCs in the peripheral blood of tumor-bearing females of different ages were all obviously higher than those in the control groups of the same ages (P all<0.001).The expression concentrations of MDSCs in the peripheral blood in the tumor node metastasis (TNM) Stage Ⅲ group were obviously higher than those in the TNM Stage Ⅰ and Ⅱ group (P<0.01),whereas there were no significant differences in the distribution of the expression concentrations of MDSCs in the peripheral blood between the younger group and the older group (P>0.05).The expression concentrations of MDSCs in the peripheral blood in the TNM group were obviously higher than those in the non-TNM group (P<0.01), whereas the distributions of the expression concentrations of MDSCs in the peripheral blood in the small tumor volume group had no significant differences from those in the big tumor volume group,histological Stage Ⅰ group, histological Stage Ⅱ group and histological Stage Ⅲ group (P all>0.05). In the comparison of the expression concentrations of MDSCs in the peripheral blood of the tumor-bearing females with breast cancer of different molecular typing, no obvious differences among Luminal A, Luminal B and HER-2 over-expression, the triple negative breast cancer and other molecular typing (P all>0.05).Conclusion:MDSCs in peripheral blood can be taken as the specific identifier for the biological auxiliary diagnosis of breast cancer, and MDSCs are closely related with the clinical TNM stages and the existence of TNM for breast cancer.
查看全文   查看/发表评论  下载PDF阅读器